In 438 patients with EGFR-mutated NSCLC progressing on third-generation EGFR TKIs, ivonescimab plus chemotherapy lengthened median PFS vs placebo plus chemotherapy (6·8 vs 4·4 months; HR 0·52); overall survival gain was not significant (HR 0·79; 95% CI 0·62–1·01).
RCTn = 438
Le et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial